Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Grothey
Biomarker Analysis Beyond Angiogenesis: RAS/RAF Mutation Status, Tumour Sidedness, and Second-Line Ramucirumab Efficacy in Patients With Metastatic Colorectal Carcinoma From RAISE, a Global Phase 3 Study
Annals of Oncology
Medicine
Oncology
Hematology
Solving Nonlinear Financial Planning Problems With 109 Decision Variables on Massively Parallel Architectures
Computational Finance and its Applications II
Related publications
Baseline Carcinoembryonic Antigen as a Predictive Factor of Ramucirumab Efficacy in RAISE, a Second-Line Metastatic Colorectal Carcinoma Phase III Trial
European Journal of Cancer
Cancer Research
Oncology
Impact of Tumour RAS/BRAF Status in a First-Line Study of Panitumumab + FOLFIRI in Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Oncologist
Cancer Research
Medicine
Oncology
Mutation Analysis of Key Genes in RAS/RAF and PI3K/PTEN Pathways in Chinese Patients With Hepatocellular Carcinoma
Oncology Letters
Cancer Research
Oncology
A Multi-Center Phase II Study and Biomarker Analysis of Combined Cetuximab and Modified FOLFIRI as Second-Line Treatment in Patients With Metastatic Gastric Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
Deficient Mismatch Repair and RAS Mutation in Colorectal Carcinoma Patients: A Retrospective Study in Eastern China
PeerJ
Genetics
Molecular Biology
Biochemistry
Biological Sciences
Medicine
Agricultural
Neuroscience
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
Impact of Primary Tumour Location on Second- Or Later-Line Treatment Outcomes in Patients With RAS Wild-Type Metastatic Colorectal Cancer and in All Lines of Treatment in Patients With RAS Mutations in Four Randomised Panitumumab Studies
Clinical Colorectal Cancer
Oncology
Gastroenterology
